AVTX — Avalo Therapeutics Share News
0.000.00%
Last trade - 00:00- $399.54m
- $1.27m
- $0.06m
Avalo Therapeutics Inc expected to post a loss of $6.70 a share - Earnings Preview
Avalo Therapeutics Inc expected to post a loss of $6.70 a share - Earnings Preview
Brief: Avalo Therapeutics Announces Active IND for AVTX-009 To Treat Hidradenitis Suppurativa
Brief: Avalo Therapeutics Names Paul Varki As Chief Legal Officer
Avalo Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Avalo Therapeutics Inc expected to post a loss of $1.18 a share - Earnings Preview
Avalo Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Avalo Therapeutics Increased Size Of Board To Nine Members
Avalo Therapeutics surges on buyout of privately held AlmataBio
Brief: Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Avalo Therapeutics Inc expected to post a loss of $4.80 a share - Earnings Preview
Brief: Avalo Therapeutics Announces 1-For-240 Reverse Stock Split
Brief: Avalo Therapeutics Gets Notice From Nasdaq on Listing Extention and Compliance Exceptions
Brief: Avalo Therapeutics - QTRLY Loss Per Share $0.11
Avalo Therapeutics Inc expected to post a loss of $1.10 a share - Earnings Preview
Brief: Avalo Therapeutics Announces Payoff of Remainder of $35 Million Debt Owed To Horizon Technology Finance Corp
Brief: Avalo Enters Into Agreement To Divest Avtx-800 Series
Avalo Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Avalo Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview